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1. Introduction 
The most recent clinical trials on adult acute lymphoid leukaemia (ALL) have shown 
complete remission and disease-free survival (DFS) rates of 80-85% and 30-40%, respectively 
(Annino, et al, Durrant, et al, Kantarjian, et al, Larson, et al, Ribera, et al, Rowe). Intensified 
consolidation, particularly with high-dose methotrexate and high-dose cytarabine, may be 
one of the reasons for the improved outcome in recent series (Bassan and Hoelzer, Hoelzer 
and Gokbuget, Kebriaei and Larson). In addition, risk-adapted and subtype-oriented 
therapy may have contributed to this better outcome. However, the long term outcome of 
adult patients is still dismal, with approximately one third of the cases only being cured. At 
present, therapeutic options include conventional chemotherapy (CHT), high dose therapy 
with autologous and, especially, allogeneic stem cells transplantation (SCT) and, for certain 
subsets, such as BCR-ABL1+ ALL, specific targeted therapy (Piccaluga, et al). 
Although SCT has been used in adult ALL for more than 20 years, its role remains 
controversial as demonstrated by conflicting results in various studies. Previous case-
controlled studies did not show that allogeneic SCT (alloSCT) provided any advantage over 
CHT  (Horowitz, et al, Zhang, et al) while in some studies there was an advantage, but 
restricted to young adults (Oh, et al). The number of controlled published or ongoing trials is 
remarkably small and some of them did not include both standard-risk and high-risk 
patients. Thus, it is difficult to draw definitive conclusions from their results. In fact, while 
some authors did not report any differences between alloSCT and chemotherapy or 
autologous SCT (ASCT)(Gupta, et al, Labar, et al), others only found differences favouring 
allogeneic SCT in standard risk (Goldstone, et al) or high-risk ALL patients (Sebban, et al, 
Thiebaut, et al, Thomas, et al).  
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In this article, the Authors reviewed data concerning alloSCT in adult ALL and discuss 
current controversial and possible perspectives.  
2. Rationale for allogeneic SCT: the graft versus leukaemia effect in ALL 
Initial studies were conduced in patients with advanced stage disease, aiming to overcome 
drug resistance by intensifying the dose of CHT and rescuing patients with syngeneic or 
allogeneic haemopoietic stem cells (SC) (Fefer, et al, Thomas, et al). In the first study, 16 
patients with refractory ALL received high dose therapy followed by infusion of syngeneic 
bone marrow (Fefer, et al). Six out of these patients achieved a durable remission, 
demonstrating the efficacy and the potential curative effect of high dose therapy in ALL. On 
the other hand, the role of donor-derived immunologic anti-leukaemic effect - so called 
“graft versus leukaemia” (GVL) effect – was first established in animal models (Chester, et 
al). The first evidence of GVL effect in humans was actually demonstrated in ALL patients 
treated with alloSCT (Mathe, et al, Thomas, et al). In this series, patients who developed 
grade ≥2 graft versus host disease (GVHD) had a significantly lower relapse rate after 
transplant if compared with patients with grade 1 or no GVHD or with those who received 
syngeneic bone marrow (p<0.01). Subsequent studies further underlined this phenomenon 
(Doney, et al, Horowitz, et al, Lee, et al), although its relevance is less convincing than in 
myeloproliferative diseases such as chronic myeloid leukaemia, or chronic 
lymphoproliferative disease and possibly lymphomas.  
3. Designation of risk factors in ALL 
There is a considerable variation in the relapse risk which can be predicted by various risk 
factors (Table 1) (Hoelzer D 2002, Moorman, et al), including unfavourable cytogenetics,  
 
  Good Adverse
Age 15-35* >50-60
35-50
WBC at diagnosis <30x109/L (B-ALL) >30x109/L (B-ALL) 
<100x109/L (T-ALL) >100x109/L (T-ALL) 
Cytogenetics del(9p) t(9;22);
high hyperdiploidy t(4;11);
t(8;14)
hypodiploidy/almost triploidy  
complex karyotype 
Time to CR < 4 weeks > 4 weeks
Immunophenotype Pre-B Pro-B
Common Pro-T
Thymic Pre-T
Mature T
MRD Negative Persistent ( ≥10-3) after induction   
Stable during follow up Increasing during treatment/follow up 
* Special benefit appear to be related in this group to the application of paediatric (i.e. intensified) regimens 
** intermediate prognosis 
WBC = white blood cells 
Table 1. Prognostic factors in adult ALL 
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poor/slow response to induction CHT, leukocyte count at diagnosis and phenotype. 
Accordingly, patients can be stratified as standard-risk (no risk factors) or high risk (one or 
more risk factors) with 45-60% vs less than 30% DFS, respectively (Hoelzer D). In particular, 
detection of minimal residual disease (MRD) after treatment was shown to be associated 
with impending relapse, independent of any other risk factor (Bassan, et al, Mortuza, et 
al)(Gazzola A et al, submitted). According to some investigators the status of MRD may be 
sufficient for stratification and the role conventional clinical risk factors appears 
questionable. 29  
4. Preparative regiments 
4.1 Ablative regimens 
Conditioning regimens used for alloSCT must ideally: 1) achieve adequate 
immunosuppression of the recipient to prevent rejection of the donor SC, and 2) destroy 
residual malignant cells while causing minimal toxicity. Most preparative regimens for ALL 
use total body irradiation (TBI) and cyclophosphamide (Cy) while some centres use 
etoposide and cytosine arabinoside (Ara-C) in addition to or instead of Cy. Busulphan-
cyclophosphamide (BU/Cy) has also been used to avoid radiation but an IBMTR study 
showed an inferior outcome with this regimen with a 3-year probability of DFS of 35% 
versus 50% when TBI and Cy were used (Davies, et al). Because most chemo-radiation 
regimens are at the limits of toxicity, any further dose escalation in an attempt to reduce the 
risk of relapse would probably increase the regimen-related toxicity to unacceptable levels, 
particularly in older or heavily pretreated patients. The addition of biological agents like 
monoclonal antibodies or radioconjugates to conventional conditioning regimens can 
potentially provide an augmented anti-leukaemic effect without increasing treatment 
related toxicity.  
4.2 Non-myeloablative regimens 
High-dose CHT and alloSCT carry substantial treatment related morbidity and mortality in 
older patients (>50 years), those with compromised organ function (e.g., congestive heart 
failure), coexisting infections, or those who were heavily pre-treated prior to SCT. In all of 
these patients, treatment-related mortality can exceed 50%, making them ineligible for SCT. 
More recently, new strategies for allografting have explored an approach of less intensive 
conditioning therapy with the aim of allowing partial engraftment of donor immune and 
haematopoietic systems with eventual replacement of the host’s own haematopoiesis and 
immunity. A variety of regimens based on low-dose TBI or fludarabine are increasingly 
used (Giralt, et al, Khouri, et al, Slavin, et al, Storb, et al). Such reduced intensity conditioning 
(RIC) regimens may be more suitable for patients with indolent malignancies where there is 
sufficient time for a graft versus malignancy effect to operate. Patient with acute leukaemia 
who have active disease transplanted with non-myeloablative regimens have a high relapse 
rate. Another major problem with submyeloablative regimens is an increased rate of graft 
failure ranging from 5% to 30% versus 1% to 5% in patients undergoing full myeloablation 
prior to alloSCT. The use of lymphodepleting antibodies or a combination of monoclonal 
antibodies in addition to cytotoxic or immunosuppressive drugs could potentially decrease 
rejection rates (Brenner, et al, Kottaridis, et al). 
Examples of preparative regimens used in ALL are summarized in Table 2. 
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Author Regimen 
Thomas et al 1982 
Vitale et al. 1983 
 
Tutschka et al. 1987 
Blume et al. 1993 
Rowe et al. 2001 
Bieri et al. 2001 
Cy 120 mg/Kg + TBI (SD 10 Gy) 
Cy 120 mg/Kg + fractioned TBI (2 Gy x6) 
 
BU 16 mg/Kg + Cy 120 mg/Kg 
Etoposide/TBI vs. BU/Cy 
Etoposide/TBI 
TBI at different doses* 
BU = busulfan; Cy = cyclophosphamide; SD = single dose 
* retrospective comparison 
Table 2. Examples of preparative regimens adopted in ALL 
5. Allogeneic stem cell transplantation for Ph-negative ALL 
Many factors need to be considered before recommending alloSCT including: 
1. Cure rate with conventional CHT; 
2. Transplant related mortality (TRM) and morbidity; 
3. Cure rate with alloSCT. 
As TRM and cure rates strongly depend on the disease phase at the time of transplant, 
different phases will be considered separately in our description. 
5.1 Acute lymphoid leukaemia (ALL) in first remission  
As the risk of transplant related mortality needs to be balanced against potential cure with 
standard CHT alone, alloSCT as post-consolidation therapy is favoured in patients who are 
at a high risk of relapse after standard CHT. While in children the likelihood of cure with 
modern intensive CHT range is 70–80% (Pui and Evans), in adults with ALL the cure rate 
with CHT is only 25–40% and, despite the intensification of CHT regimens, the majority of 
patients will relapse and die of their disease (Bassan and Hoelzer). In particular, the 
presence of any risk factor (Table 1) reduces the chance of long-term DFS with CHT to 
between 15% and 25%, making the patient a candidate for allografting in first remission 
(CR1). In fact, alloSCT in CR1 was suggested to provide a better anti-leukaemic effect and to 
improve patients’ outcome compared with a conventional post-remission CHT regimen.  
Retrospective studies evaluating the role of alloSCT in CR1 were encouraging with DFS 
ranging between 40 and 63% and relapse rates of 10-40% (Barrett, et al, Blume, et al, Blume, 
et al, Chao, et al, De Witte, et al, Thomas, et al, Vernant, et al, Vey, et al). However, most of the 
studies were small (with less than 50 patients each) and were limited by selection bias (see 
Table 3 for details). In addition, few studies retrospectively compared alloSCT vs. 
autologous SCT (ASCT) or CHT in ALL performed in CR1. None of these studies showed an 
improved survival in transplanted patients (Table 4). In particular, Horowitz and 
Colleagues, on behalf of the IBMTR, reported the outcome of adult ALL patients (aged 15-45 
years) treated with intensive CHT (IC, N=484) vs. allogeneic SCT (N=251) in CR1 (Horowitz, 
et al).  
Allografted patients had significantly reduced risk of relapse (26% vs. 59%). However, the 
DFS was not superior after SCT, reflecting the higher mortality rate observed after SCT (38% 
vs. 4%) (Horowitz, et al). 
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Author Number of 
patients/ 
characteristics 
Age GVHD grade 
2-4 (%) 
TRM 
(%) 
RR 
(%) 
5-y DFS 
(%) 
Blume et al. 1987 
Vernant et al. 1988 
Barrett et al. 1989 
Chao et al. 1991 
Vey et al. 1994 
De Witte et al. 1994 
38 
27 
243 
53/high risk 
29 
22/high risk 
16-41 
15-36 
16-48 
1-45 
16-41 
15-51 
31 
44 
40 
11 
27 
NA 
26 
30 
37 
28 
29 
23 
16 
11 
30 
10 
10 
23 
63 
59 
39 
61 
62 
58 
GVHD=graft versus host disease 
TRM=transplant related mortality 
RR=relapse risk 
5-y DFS=disease free survival at 5 years 
Table 3. Retrospective non-comparative studies considering alloSCT in ALL 
Only few studies prospectively compared alloSCT to other post-remission strategies in ALL 
(Table 4) (Attal, et al, Fielding, et al, Fiere, et al, Goldstone, et al, Hunault, et al, Rowe, Sebban, 
et al, Thiebaut, et al), (Labar, et al). The BGMT group conduced a prospective trial evaluated 
alloSCT vs. ASCT in CR1. According to genetic randomization, patients with (n = 43) or 
without an HLA-identical sibling (n = 77) were assigned to receive allogeneic or autologous 
SCT, respectively. The 3-year post-CR probability of DFS was significantly higher in the 
HLA-identical sibling group than in the non-HLA-identical sibling group (68% v 26%; 
P<0.001) (Attal, et al). Recently, the 10-year follow-up results confirmed the marked 
superiority of alloSCT to CHT in terms of survival (44 vs 11%, P=0.009)(Marks, et al).   
The prospective randomized LALA87 trial compared alloSCT  vs. ASCT/CHT. Patients 
aged 15-40 years who achieved CR and had a matched related donor were assigned to 
allograft, whereas those without a donor were randomized to receive ASCT vs CHT. 
Seventy-six percent (436/572 evaluable patients) achieved CR. Intention to treat analysis, 
comparing patients assigned to alloSCT (N=116) vs. ASCT/CHT, showed increased survival 
in allografted patients (10 years overall survival – OS- 46% vs. 31%, p=0.04). In high risk 
patients, the advantage was more evident (44% vs. 115, p=0.009). On the contrary, standard 
risk patients did not significantly benefit from SCT (p=0.06) (Thiebaut, et al). 
The GOELAL02 trial evaluated the impact in high risk ALL patients of early alloSCT or 
delayed unpurged ASCT for patients who had no HLA–matched sibling donor or who were 
older than 50 years. Among 198 patients, the median age was 33 years. The CR rate was 80% 
with standard induction therapy. AlloSCT was performed after 2 consolidation courses 
while ASCT was delayed after 1 additional reinduction. Intensified conditioning regimen 
before transplantation included etoposide, cyclophosphamide, and total body irradiation 
(TBI). Median follow-up was 5.1 years. The median overall survival (OS) was 29 months, 
with a 6-year OS of 41%. On an intent-to-treat analysis for patients younger than 50 years, 
alloSCT significantly improved the 6-year OS (75% versus 40% after ASCT; P = .0027). On 
the other hand, randomized interferon-  maintenance had no effect on relapse or survival 
after ASCT (Hunault, et al).  
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In the EORTC ALL-3 study, Labar and collegues evaluated the role of alloSCT based on a 
genetic randomization.(Labar, et al). Patients achieving CR and having an HLA-identical 
sibling were intended for alloSCT after completion of consolidation while the remaining 
ones were randomized to receive either ASCT or maintenance. Among 68 patients in the 
donor arm the transplantation was performed in 47 cases. According to the intention-to-
treat analysis the incidence of relapse at 6 years was decreased (38% vs. 56%) while the 
incidence non-relapse mortality increased (24% vs. 7%) in the “donor” compared with “no 
donor” arm. The probability of DFS was superimposable (38% vs. 37%, respectively). 
Among 116 patients lacking a donor only 45 were randomized making the  vs. maintenance 
comparison statistically underpowered. 
Recently, Ribera and Colleagues reported on 222 high risk ALL patients enrolled in the 
PETHEMA ALL-93 trial (Ribera, et al). All received a standard five-drug/five-week 
induction course. Patients in CR with an HLA identical family donor were assigned to 
alloSCT (n=84) and the remaining were randomized to ASCT (n=50) or to delayed 
intensification followed by maintenance CHT up to 2 years in complete remission (n=48). 
Overall, 183 patients achieved complete remission (82%). With a median follow-up of 70 
months, the median DFS and OS were 17 and 23 months, respectively. The 5-year DFS and 
OS were 35% (95% CI, 30%- 41%) and 34% (95% CI, 28%-39%), respectively. Patients 
allocated to the CHT, allogeneic and autologous SCT were comparable in the main pre-
treatment ALL characteristics and the rate of response to therapy. Intention-to-treat analysis 
showed no differences between patients according to whether they had or did not have a 
donor in DFS (39%, 95% CI 30-48% vs. 33%, 95% CI 23-41%) and OS (44%, 95% CI 35- 52% 
vs. 35%, 95% CI 25-44%), as well as for autologous SCT vs. CHT comparisons (DFS: 40%, 
95% CI 28-52% vs. 51%, 95% CI 37-67%; overall survival: 43%, 95% CI 29-58% vs. 52%, 95% 
CI 39-65%). No differences were observed when the analysis was made on the basis of the 
treatment actually performed (Ribera, et al). 
More recently, the final results of the MRC UKALL XII/ECOG 2993 protocol were available, 
regarding a large prospective randomized study aiming to establish the best post-remission 
therapy for adult ALL (Avivi and Goldstone, Rowe, et al, Rowe). In this study, patients 
(N=1,646) received 2 phases of induction and, if in remission, were assigned to allogeneic 
transplantation if they had a compatible sibling donor. Other patients were randomized to 
chemotherapy for 2.5 years versus an ASCT. A donor versus no-donor analysis showed that 
Ph- patients with a donor had a 5-year improved OS (53% versus 45%; p = .01), and the 
relapse rate was significantly lower (p ≤ .001). The survival difference was significant in 
standard-risk patients, but not in high-risk patients due to a high treatment related mortality 
(TRM) in the high-risk donor group. Interestingly, patients randomized to chemotherapy 
had a higher 5-year OS (46%) than those randomized to autologous transplantation (37%; p 
= .03) (Goldstone, et al). Importantly, a dedicated analysis was carried on Ph+ cases (N=267) 
(Fielding, et al). In this setting, in the comparison of the outcome after any alloSCT with the 
outcome after chemotherapy alone, OS (p = .001), EFS (p < .001), and RFS (P < .001) were all 
significantly superior for patients receiving any alloSCT over those receiving chemotherapy 
alone. Of note, there was a marked difference in the cause of death between alloSCT and 
chemotherapy recipients. Whereas the leading cause of death in chemotherapy treated 
patients was relapse, the leading cause of death after transplantation was TRM, which was 
27% after sibling-SCT and 39% after VUD-SCT (Fielding, et al). 
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Author Post-remission 
therapy 
Number of 
patients 
Age  TRM (%) RR (%) 5-y DFS 
Blaise et al. 
1990 
Allo vs. Auto 25 vs. 22 4-36 vs. 7-47 20 vs. 9 9 vs. 57 71 vs. 40 
Horowitz et al. 
1991 
Allo vs. CHT 234 vs. 484 15-45 vs. 15-
45 
39 vs. 4 26 vs. 59 44 vs. 38 
Attal et al. 
1995 
Allo vs. Auto 43 vs. 77 15-55 vs. 15-
55 
12 vs. 2 12 vs. 62 68 vs. 26 
(3-y) 
Oh et al. 1998 Allo vs. CHT 127 vs. 38 <30 32 vs. 3 22 vs. 69 30 vs. 30 
  Allo vs. CHT 87 vs. 38 >30 NA 37 vs. 70 30 vs. 26 
Fiere et al. 
1993 
Allo vs. Auto vs. 
CHT 
116 vs. 95 vs. 
96 
15-40 vs. 15-
50 
18 37 46 vs. 39 
vs. 32 
Fiere et al.1998 Allo vs. Auto vs. 
CHT 
116 vs. 95 vs. 
96 
15-40 vs. 15-
50 
NA NA 46 vs. 34 
vs. 30 
Rowe et al. 
2001 
Allo vs. 
Auto/CHT 
190 vs. 253 15-50 vs. 15-
50 
NA 24 vs. 60 52 vs. 36 
Hunault 2004 Allo vs. Auto* 41 vs. 115 15-52 vs. 15-
57 
15 vs. 3 10 vs. 49 75 vs. 38 
Labar et al. 
2004 
Allo vs. (Auto or 
CHT) 
68 vs. 116 <50 24 v.7 38 vs. 56 38 vs. 37 
Ribera et al. 
2006 
Allo vs. Auto vs. 
CHT 
84 vs. 50 vs. 
48 
16-49 vs. 15-
50 vs. 15-50 
8 vs. 3 vs. 
0 
62 vs. 57 
vs. 46 
44 vs. 54 
vs. 45 
Goldstone et 
al. 2009 
Allo vs. 
CHT/ASCT 
443 vs. 588 <54 vs. < 64 36-20% vs. 
14-7% 
24% vs. 
49% 
53% vs. 
45%§ 
* early alloSCT vs. delayed ASCT 
TRM=transplant related mortality 
RR=relapse risk 
5-y DFS=disease free survival at 5 years 
§ Overall survival 
Table 4. Studies comparing alloSCT vs. CHT/ASCT in ALL 
5.2 ALL in second remission  
More than 50% of adult ALL patients will relapse after initial CR. Half of these patients will 
actually obtain a second CR (CR2) following re-induction therapy. However, CR2 is not 
durable and only less of 10% of the patients will be cured with CHT or ASCT. By contrast, 
DFS after alloSCT performed in CR2 approaches 25-38% (Avivi and Goldstone, Herzig, et al, 
Thomas, et al). Indeed, alloSCT appears to be the best option for patients in CR2, 
irrespectively of the initial risk factors. However, unfortunately, no randomized trials 
compared alloSCT and CHT in this setting. Noteworthy, the outcome of alloSCT in CR2 is 
also affected by CR1 duration, being definitely better when CR1 was longer than 24 months 
(Forman, Kersey, et al, Thomas, et al). 
5.3 ALL after second relapse or primary induction failure  
Once patients are beyond second remission, the results of all allografting procedures worsen 
considerably, with only 10–15% of patients becoming long-term disease-free survivors 
(Goldman, et al, Storb, et al). Similarly, the outcome with transplant is poor with only 10–
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15% DFS for patients who fail primary induction therapy. However, though  these results 
are not brilliant, SCT still offers the only prospect of cure (Biggs, et al). Biggs et al reported 
23% DFS in 38 ALL patients treated with alloSCT for primary induction failure disease; the 3 
years probability of persistent/recurrent disease was 59% (Biggs, et al). The result is, 
however, encouraging with almost one quarter of patients rescued after initial treatment 
failure. On the other hand, it should be considered that 26% of the cases in this study were 
aged under 19 years (and 8 less under 10) and 39% achieved a partial remission before 
transplant. TRM was significantly higher in patients older than 30 years or with poor 
performance status (PS). Thus, it appears that 10-20% of patients who fail to achieve CR after 
induction can benefit from alloSCT; however, patients to be referred to this procedure 
should be carefully selected basing on age and PS. 
6. Stem cell transplantation for Ph+ ALL 
The presence of Ph chromosome is one of the most relevant adverse prognostic factors in 
ALL. To date, alloSCT is the unique approach which can be considered as potentially 
curative, thus being the treatment of choice in adult Ph+ ALL (Avivi and Goldstone, Barrett, 
et al, Chao, et al, Dombret, et al, Fielding, et al, Ottmann and Pfeifer, Piccaluga, et al, 
Piccaluga, et al). Twenty-seven to 65% long-term survival has been reported for patients 
undergoing alloSCT in first complete remission (CR1), (Avivi and Goldstone, Fielding, et al). 
Unfortunately, relapse occurs in approximately 30% of patients, representing the primary 
cause of treatment failure together with treatment-related mortality, which increases with 
age and advanced disease (Avivi and Goldstone, Martin and Gajewski). Achievement and 
maintenance of a CR prior to SCT is an important prerequisite for a favourable outcome 
after SCT (Wassmann, et al). In fact, when performed further than first remission, only a 
small minority of patients can be cured by alloSCT; nevertheless, in such cases, although 
 
 Author 
 
N TRM REL Outcome
Barret et al, 1992
 
33
22
42%
40%
34%
32%
38% at 2 years (DFS) 
41%
Chao et al, 1995 38 NA NA 46% (CR1) at 2 years (DFS) 
28% (>CR1) 
Snyder et al, 
1999 
23 30% 12% 65% at 3 years (DFS) 
Goldstone et al, 
2001 
72 37% (Sib) vs 43% (VUD) 32% 42% at 5 years (DFS) 
Dombret et al,
2002 
56 25% 37% 37% at 3 years (OS) 
Fielding et al, 
2009 
267 27% (Sib.) vs. 39% (VUD) 32% 41%-36%* at 5 years (EFS) 
44%-36%* at 5 years (OS) 
N= number of patients 
TRM= transplant related mortality 
REL= relapse rate 
DFS= disease free survival 
CR1= first complete remission 
* Sibling donor vs. VUD 
Table 5. Results of allogeneic stem cells transplantation in adult Ph+ ALL 
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the probability of success is limited, alloSCT may be still curative in a subset of patients and 
it remains the treatment of choice (Garcia-Manero and Thomas). The probability of DFS 
(DFS) at 2 years after alloSCT in second or third remission or as salvage therapy for 
refractory disease has been reported to be 17% and 5%, respectively (Cornelissen, et al). In 
patients failing allogeneic SCT, further treatment is rarely successful. With this regard, the 
availability of novel tyrosine-kinase inhibitors (TKI), including imatinib, dasatinib and 
nilotinib, has became of great interest (Piccaluga, et al). In fact, TKI either can be added to 
CHT potentially increasing the number of patients to be referred to alloSCT in CR1 
(Wassmann, et al), and constitutes a possible salvage treatment in case of relapse after 
alloSCT (Olavarria, et al, Wassmann, et al). 
Results with allogeneic stem cells transplantation are summarized in Table 5 (Avivi and 
Goldstone, Barrett, et al, Chao, et al, Fielding, et al, Snyder, et al). 
7. Source of stem cell for allogeneic transplantation 
7.1 Bone marrow versus mobilized peripheral blood  
Cytokine-mobilized allogeneic peripheral blood stem cell (PBSC) harvest has become an 
alternative to bone marrow as a source of stem cells for matched-sibling transplants. Early 
phase II studies showed that this source of stem cells resulted in faster engraftment, no 
increase in acute GVHD (perhaps due to a G-CSF-mediated shift to Th2 helper cells) but an 
increased incidence of chronic GVHD (Bensinger, et al, Korbling, et al). A prospective 
randomized study of allogeneic PBSC compared to marrow showed a 2-year actuarial 
overall survival of 54% in patients receiving marrow compared with 66% in those receiving 
PBSCs (Bensinger, et al). Differences in survival were significant for patients with 
unfavourable-risk diseases but not for those with favourable-risk diseases (Bensinger, et al). 
Faster engraftment, similar GVHD and improvement in overall survival was also reported 
in a Canadian and New Zealand study (Couban, et al). In a retrospective multivariate 
analysis from the IBMTR comparing the results of 288 HLA-identical sibling blood stem cell 
transplants with the results of 536 HLA-identical sibling bone marrow transplants, the 
relapse incidence between the two transplant groups did not differ significantly (Champlin, 
et al). However, treatment-related mortality rates were lower and leukaemia-free survival 
rates were higher with use of blood stem cell transplants in patients with advanced versus 
early leukaemia  (Champlin, et al). While the results of more studies should become 
available over the next few years, the current experience suggests that peripheral blood 
should be the preferred source of stem cells for patients with high-risk disease and/or 
advanced phase. For patients with low-risk disease, the increased risk of chronic GVHD 
needs to be balanced against the risk of relapse. 
7.2 Alternative donor sources 
Most patients do not have a suitable histocompatible sibling donor for an allograft and the 
use of alternative donors such as voluntary unrelated donor (VUD),  haploidentical donor 
and umbilical cord blood (UCB) grafts. As regards VUD, the results are actually comparable 
to those obtained with matched sibling donors and many groups routinely refer to this 
source for patients in CR1. Conversely, to date, the other two options have been mainly 
reserved for patients in ≥CR2. Few large-scale studies compare these forms of alternative 
donor transplantation and the choice of stem cell source will also be influenced by clinical 
www.intechopen.com
 
New Advances in Stem Cell Transplantation 
 
276 
urgency and the time taken to procure haematopoietic stem cells. Single centre results must 
be analysed carefully when deciding what plan to recommend in the individual patient.  
If a matched donor is not available, some data indicate that a single antigen mismatched 
family donor allograft may result in the same outcome as using a matched UD, but a 
perspective randomized comparison has never been performed. In general, if there is no 
molecularly matched UD, then a single allele mismatched UD, an UCB donor or a 
haploidentical stem cell donor could be considered as possible alternative (Marks, et al).  
In this regard, few small studies focused on the use of UCB in ALL, and basing on these data 
it is difficult to advise investigators how to approach potential patients. Small patient 
numbers, heterogeneity of remission status, variability of matching and incomplete 
information about UCB cell dose make data summary difficult. In general, these results are 
promising, but relapse remains a significant issue as well as does engraftment failure. 
Somewhere between 20 and 50% of patients in CR1 and an occasional CR2 patient can 
become long-term survivors. Double UCB transplants or intra-bone SC infusion (Castello, et 
al) may represent an advance, particularly addressing the issue of engraftment.  
Haploidentical transplant have the major advantage of donor availability and results have 
been possibly improved. In particular, the high rejection rate and incidence of severe GVHD 
are reduced by combining high-intensity conditioning and an infusion of a large dose of 
purified SC in adult ALL patients transplanted in CR1 or CR2. These data, however, have 
not been corroborated in multi-centre trials, and a variety of opportunistic infections 
continue to plague this approach that does not appear useful in the setting of advanced 
disease. Further avenues of improvement include the exploration of killer cell 
immunoglobulin-like receptor (KIR) mismatching between donor grafts and recipients. 
Data on alternative donor source in ALL have been recently reviewed by Marks et al 
(Marks, et al) and are summarized in Tables 6-7. 
8. Post transplant strategies to improve clinical outcome 
8.1 GVHD prophylaxis 
GVHD results from alloreactivity between donor and recipient. The two major prophylactic 
regimens employed to prevent this complication are pharmacological (administration of 
immunosuppressive drugs), and immunological (in vitro T-cell depletion). The standard 
pharmacologic prophylaxis has been cyclosporine (CsA) and short-course methotrexate, but 
recent studies suggest that the incidence of GVHD may be lower if FK506 is substituted for 
CsA (Nash, et al). MMF also shows promise in animal models, and its combination with CsA 
is being evaluated in clinical trials. Ex vivo T-cell depletion reduces the risk of both acute 
and chronic GVHD and may allow higher tolerance of mismatching but may also increase 
the risk of rejection and delay immune reconstitution. A confounding feature for 
interpreting the value of T-cell depletion is that a variety of methodologies are employed to 
remove T cells, including physical methods, poly- and mono-clonal antibodies. Some 
techniques produce a pan-T depletion, whereas others use antibodies with more restricted 
T-subset specificities. An IBMTR study showed a better outcome when antibodies with 
narrow specificities are used (Champlin, et al). 
8.2 Reducing the risk of relapse 
The major cause of failure after transplant for ALL is relapse. The outcome of patients who 
relapse after allogeneic SCT is very poor. Remissions are possible with standard CHT but 
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are not durable. Those who relapse more than 1-year post-transplant are more likely to 
achieve a further remission. Donor leukocyte infusions have been used but their success rate 
in patients with ALL is much lower than in patients with myeloid malignancies (Porter and 
Antin). Strategies to reduce the risk of relapse include intensifying conditioning regimens, 
altering the timing of transplant and augmenting the graft versus leukaemia effect. The risk 
of relapse may also be reduced by more precisely defining the biological risk factors that 
justify transplant in first remission, thus circumventing the possibility of selecting for 
leukaemia resistance during prolonged CHT. Patients who receive an alloSCT for ALL and 
develop graft versus host disease (GVHD) have a lower probability of relapse than patients 
who do not suffer this complication. A recent study showed that in patients with high levels 
of minimal residual disease (MRD) pre-transplant, the presence of acute or chronic GVHD 
may be needed to prevent relapse(Uzunel, et al). The likely explanation for this observations 
is that the alloreactive T cells in the donor graft are able to destroy residual host leukaemia 
cells. In support of this contention, administering lower doses of CsA reduces the relapse 
risk and improves DFS in children undergoing SCT for leukaemia (Locatelli, et al). Adoptive 
immunotherapy with donor mononuclear cells is less successful in ALL than in the myeloid 
leukaemias, although there is some evidence that use of immunostimulatory cytokines such 
as IL2 may amplify graft versus leukaemia mechanisms and induce remissions in patients 
who have failed to respond to donor lymphocyte infusions. Immune modulation post-
transplant may therefore be a therapeutic alternative to reduce the risk of relapse. One 
means of reducing the risk of GVHD is to administer antigen-specific cytotoxic T-cell lines 
(CTL) lines when a specific antigen is known. Potential targets include minor antigens 
differentially expressed on haemopoietic cells  (Mutis, et al) or lineage specific antigens, such 
as WTI or proteinase 3 (Ohminami, et al). Such lines could potentially mediate cytotoxic 
activity directed at recipient haemopoiesis (and leukaemia) but not donor haemopoiesis. An 
alternative approach when a tumour antigen is not defined is to increase the 
immunogenicity of the tumour and allow selection of the tumour antigen by responding 
immune system effector cells. This approach has shown efficacy in a number of animal 
models using molecules that modify antigen presentation such as Class I MHC molecules or 
GMCSF, co-stimulatory molecules such as B7 or T-cell activation factors such as IL2. For 
example pre B ALL cells lack B7-1(CD80) and induce allo-specific T-cell anergy. If ALL cells 
are transduced with B7, their antigen presentation capacity is improved and they are able to 
generate autologous leukaemia-specific CTL lines from marrow from the majority of 
patients (Cardoso, et al). Murine data also suggests that combination of molecules acting on 
different phases of the immune response may produce increased anti-tumour activity 
(Dilloo, et al) and this approach is currently being tested in a clinical trial in patients with 
ALL (Rousseau, et al). 
9. Autologous stem cell transplantation 
The role of  in adults with ALL has not been clearly defined. Prospective studies comparing  
with alloSCT in high-risk patients demonstrated increased risk of relapse and reduced 
probability of survival in the autologous setting (Attal, et al, Hunault, et al). Trials comparing  
with maintenance chemotherapy did not show survival benefit from high-dose treatment, 
however, a pooled analysis of three subsequent trials by the French group (LALA-85/87/94) 
suggested that ASCT may contribute to decreased risk of relapse (66% vs. 78%, p=0.05) 
(Dhedin, et al, Labar, et al, Ribera, et al, Thiebaut, et al). In the MRC UKALLXII/ECOG 2993 
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study investigators tested if ASCT may be administered instead of consolidation + 
maintenance for patients lacking an HLA-identical sibling, irrespective of the presence of 
risk factors. OS was significantly worse in the ASCT compared to chemotherapy arm (46% 
vs. 37% at 5 years, p=0.03) leading to conclusion that early ASCT cannot substitute 
consolidation. 
Disappointing results of prospective trials evaluating the role of ASCT led to a general 
tendency to abandon this treatment option in adults with ALL. It must be stressed, however, 
that in view of current knowledge design of the studies could have been suboptimal. First of 
all, the trials have been conducted before the era of routine MRD assessment. Low tumor 
burden is prerequisite of successful ASCT as in other conditions the transplant material may 
be contaminated by residual leukemic blasts leading to their re-transplantation and early 
relapse. Evaluation of MRD status in bone marrow reflecting the tumor load may therefore 
be crucial for selection of patients who could benefit from ASCT. Indeed, in a retrospective 
analysis by the European Working Group for Adult ALL, the MRD level was demonstrated 
the most important prognostic factor with DFS of 58% for patients with MRD<0.1% vs. 19% 
for those with MRD ≥0.1% in bone marrow (p=0.0002) (Giebel, et al). In a setting of 123 
ASCT recipients with HR ALL, the incidence of non-relapse mortality was 2.4%. In the 
analysis of a selected group of 50 patients in whom the MRD was evaluated with sufficient 
sensitivity to define the MRD status as negative at the level of 0.01%, the 5-years probability 
of DFS was 69%. 
In so far conducted prospective trials ASCT was administered instead of either maintenance 
or consolidation + maintenance and was considered the last stage of the treatment. There is, 
however, another option, which has not been prospectively tested i.e. incorporating ASCT in 
consolidation, followed by maintenance. Interim analysis of a retrospective study by the 
Central and Eastern Leukemia Group indicate significantly increased probability of the DFS 
if maintenance based on mercaptopurine + methotrexate was administered after ASCT (70% 
vs. 38% at 5 years, p=0.03). The effect was independent on the MRD status (HR=2.6, 
p=0.007) (unpublished data). 
Finally, ASCT followed by interferon alpha administration has been shown to be quite 
effective for Ph+ patients (Piccaluga, et al, Visani, et al). 
Taken together, ASCT is associated with low risk of transplant-related mortality and 
morbidity. Its efficacy should still be prospectively evaluated in patients with low MRD 
level, with post-transplant maintenance as an option. 
10. Conclusion 
Data from clinical trials trying to compare alloSCT and other post-remission therapies for 
ALL  patients in CR1 are sometimes difficult to interpret because of varying proportions of 
patients with different risk factors in each study (some of them are actually limited to high 
risk patients as many centres do not include alloSCT in the therapeutic program of standard 
risk patients in CR1). Prospective randomized studies have been carried out by various 
cooperative groups. These studies have compared patients with HLA identical siblings 
assigned to the allogeneic SCT group to those without HLA identical sibs assigned to either 
a standard chemotherapy or ASCT group. However, as up to 70% of adults with ALL 
cannot be allocated to SCT because of a lack of a matched related sibling, comorbidities, or 
severe infections, an objective and unbiased comparison among treatments is difficult (Avivi 
and Goldstone, Martin and Gajewski, Popat, et al). A major limitation of these studies is that 
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the proportion of patients in the allogeneic SCT group actually undergoing transplant varies 
from study to study. Despite this limitation, a donor versus no donor comparison is the best 
way to answer the question about role of allogeneic SCT in first remission, even though the 
so called “genetic randomization” (based on the availability of HLA-matched donor) is not a 
proper randomization. In addition, in some studies, patients receiving ASCT/CHT included 
cases over 50 years not suitable for alloSCT. Notable features of all these studies include a 
high treatment related mortality and a lower risk of relapse in allogeneic transplant arm. On 
the other hand, the most recent study from the MRC/ECOG group (MRC UKALL 
XII/ECOG E2993) (Fielding, et al, Goldstone, et al) represented the largest series in which the 
role of alloSCT in ALL was prospectively evaluated. Indeed, in this study alloSCT was 
shown to provide the best outcome specially in standard risk patients, thus offering a strong 
indication to this procedure in the majority of ALL cases. 
On the other hand, the randomized studies so far available did not compare alloSCT to the 
most recent risk-adapted, intensified consolidation schedules, which provided significant 
benefits in terms of both relapse free and overall survival in standard risk ALL cases (Bassan 
and Hoelzer). In addition, not all the patients can benefit from it, at present. Thus, 
optimizing SCT strategies (see above) as well as improving post SCT therapy are necessary. 
In this light, the possible interventions regards either cellular therapies and pharmacological 
approaches. For example, the development of grade ≥2 GVHD is correlated with reduced 
relapse rate but relevant morbidity and mortality are related to GVHD. Thus, future 
strategies should consider graft manipulation aiming to maintain GVL effect though 
reducing GVHD and TRM.  
Finally, the presence of minimal residual disease after SCT is associated with impending 
relapse. Thus, careful MRD monitoring after SCT should be performed  and treatment of 
molecular relapse should be considered. In this setting, targeted therapy, such as TKI and 
interferon alpha (Piccaluga, et al) or novel TKI for Ph+ ALL, FLT3 inhibitors for MLL+ cases, 
nelarabine/forodesine for T-ALL and, more in general, monoclonal antibodies (anti-CD19, 
anti-CD20, anti-CD22 and anti-CD33) surely warrants further evaluation in clinical trials. 
Accordingly, based on the currently available data, allogeneic SCT is a reasonable treatment 
option for adults with high-risk and possibly standard risk ALL in CR1. Patients in CR2 
with matched donor should be probably always referred to alloSCT unless major clinical 
contraindications are recorded. Finally, refractory patients as well as cases beyond CR2 
should be carefully evaluated and selected for alloSCT basing on age, PS and amount of 
previous CHT. 
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